Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
34,214,537
-
Share change
-
-5,248,203
-
Total reported value
-
$251,478,266
-
Put/Call ratio
-
9.1%
-
Price per share
-
$7.35
-
Number of holders
-
61
-
Value change
-
-$37,500,914
-
Number of buys
-
38
-
Number of sells
-
22
Institutional Holders of ALPINE IMMUNE SCIENCES INC - COM (ALPN) as of Q4 2022
As of 31 Dec 2022,
ALPINE IMMUNE SCIENCES INC - COM (ALPN) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,214,537 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, GREAT POINT PARTNERS LLC, Lynx1 Capital Management LP, Frazier Life Sciences Management, L.P., Paradigm Biocapital Advisors LP, Omega Fund Management, LLC, BlackRock Inc., VANGUARD GROUP INC, and COMMODORE CAPITAL LP.
This page lists
61
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.